What question did this study set out to answer?

This study aims to assess the screening practices and therapeutic strategies for LDL-C and HbA1c in ACS patients.

June 12, 2026European Journal of Preventive CardiologyOpen Access

Assessment of LDL-C and HbA1c screening and management in a real-world ACS cohort in the west of Ireland

View Full Paper

Ask AI

Bookmark

Why the study?

Does dual lipid-lowering therapy improve the achievement of LDL-C targets compared to statin monotherapy in patients following acute coronary syndrome?

Population

144 patients admitted for acute coronary syndrome at a University Hospital in the West of Ireland, mean age…

Comparison

Dual lipid-lowering therapy prescribed at… vs Statin monotherapy prescribed at discharge.

Design

Cohort

Follow-up

median 9.6 weeks (IQR 6.1–16.2)

Authors

DFD FarrenUniversity Hospital Galway EFE O' FlahertyUniversity Hospital Galway CKC KavanaghUniversity Hospital Galway

Discussion

Member takes

Implication

Persistent LDL-C gaps after ACS warrant systematic follow-up; leaves open optimal real-world strategies in observational cohorts.

Key Points

This study aims to assess the screening practices and therapeutic strategies for LDL-C and HbA1c in ACS patients.
Conducted a retrospective review of ACS admissions at a University Hospital from January to July 2025.
Recorded baseline characteristics, screening rates, therapies prescribed at discharge, and follow-up LDL-C measurements.
Evaluated associations between treatment strategies and achieving LDL-C targets.
Screening rates for LDL-C were high, with 95.8% of patients screened at baseline.
Among 107 patients with follow-up measurements, the proportion achieving LDL-C targets improved significantly for dual therapy from 42.1% to 89.5%.
Nearly half of patients remained above LDL-C targets, emphasizing the need for systematic follow-up.

Structured PICO

Does dual lipid-lowering therapy improve the achievement of LDL-C targets compared to statin monotherapy in patients following acute coronary syndrome?

Population

144 patients admitted for acute coronary syndrome (ACS) at a University Hospital in the West of Ireland (STEMI 50.7%, NSTEMI 34.0%, UA 15.3%), mean age 66.1 ± 12.2 years.

Intervention

Dual lipid-lowering therapy (statin + ezetimibe) prescribed at discharge.

Comparator

Statin monotherapy prescribed at discharge.

Outcome

Achievement of LDL-C targets (<1.4 mmol/L) at follow-up.surrogate

Real-world data demonstrates that while initial post-ACS lipid screening is high, follow-up testing is underutilized, and dual lipid-lowering therapy is significantly more effective than statin monotherapy at achieving ESC LDL-C targets.

Cite This Study

Farren et al. (2026) studied this question.

synapsesocial.com/papers/6a2bd11d6550ea4541ffe8c1 https://doi.org/10.1093/eurjpc/zwag249.226

View Full Paper

Ask AI

Bookmark